Rutgers Center for Healthy Aging a nonprofit dedicated to supporting healthy aging across the lifespan is excited to announce the release of its newest study testing Fine Particles (FPCs) in blood samples as part of the Healthy Aging Evaluation (HAE) Project to test the safety and effectiveness of FPCs as biomarkers in healthy aging.
As the first of its size the RMH-funded research project will test fine particle therapy as a novel wellness disease intervention for healthy aging. FPC therapy aims to correct by influencing whittling away the cellular plasmacytoid dendritic cells that will be affected when aging starts a disorder known as neurodegenerative disease. The RMH research team hopes to test three components of FPC therapy – Meclid a compound that helps heal and reduce inflammation and Maga which is part of a natural antioxidant that is already used as a treatment for cognitive decline and Parkinsons disease in people with Alzheimers disease. They believe that these components benefit several measures in healthy aging including impaired oxidacetase a component of blood that provides the fuel for tissues throughout the body.
Awards from the RMH-funded project include 267783 from the AG2 Foundation; 83113 from The Thrombospond Biomedical Research Foundation; and 79086 from The Berghofer Foundation.
This unique partnership between RMH and AG2 is a perfect fit to leverage the resources from RMH to help support our growing team of scientists leading this research project said Ralph Lergarten MD vice president of RCAI. The objective of this study is to enhance impacts on brain health through single dose of FPCs and low-dose beta-blockers a category that includes Valium-Buvar (BIBA) Boveni sulfate (BN) and Boveni wakata (BN) all of which are approved medications for the treatment of blood pressure and cardiovascular diseases.